Fair Value Distribution — percentile bands
64.4% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
1.9%/yr
±5.3% · revenue growth to justify current price
FCF-Based Reverse DCF
17.7%/yr
±3.0% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockGE HealthCare Technologies Inc.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
GEHC FY2025: Solid healthcare recovery thesis undermined by 2025 tariff materiality. Company explicitly warned tariffs materially hurt profitability; mitigation insufficient. Imaging capex cycle impro...